Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Biosystems, EBI, SIB, PIR, Agilent Technologies, European Bioinformatics Institute


Ciphergen Biosystems, in collaboration with the American Red Cross, will commercialize Protein Equalizer beads, a technology to detect low-abundance proteins in serum samples. The technology uses a combinatorial bead library to concentrate low-abundance proteins and dilute high-abundance proteins.

The EBI, SIB, and PIR have released UniProt 2.0. The database, updated biweekly, contains 1,487,788 entries and can be accessed online at A description of changes made to Uniprot since release 1.0 can be found at

Agilent Technologies has introduced the Multiple Affinity Removal Column, an immunoaffinity HPLC column to remove high-abundance proteins from mouse blood serum. The column removes albumin, immunoglobulin G and transferrin, the three most common proteins found in mouse serum.

The European Bioinformatics Institute has launched Integr8, a browser that assembles information from 179 completely sequenced genomes and their predicted proteomes, which was previously dispersed. Integr8 is available at

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.